Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Voyager Life pays "very fair price" for CBD facility in Poland

Voyager Life PLC

Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

December 19, 2022 08:10 AM Eastern Standard Time

Video

Proactive research analyst on Numinus Wellness' annual results

Numinus Wellness Inc.

Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

December 19, 2022 08:02 AM Eastern Standard Time

Video

SkinBioTherapeutics will "continue to be flexible enough to adapt to opportunities"

SkinBioTherapeutics PLC

Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

December 19, 2022 06:14 AM Eastern Standard Time

Video

New Cloud Platform “STB CLOUD” Disrupts AI Drug Discovery Worldwide (KOSDAQ:226330.KQ)

Syntekabio, Inc.

Syntekabio (KOSDAQ:226330.KQ), a global AI drug discovery and development company, has launched STB CLOUD worldwide. Running on Syntekabio’s own supercomputing infrastructure, the new AI drug discovery cloud platform is driven by genomic big data and the latest AI technology. It can process small molecule drug discovery on any device, anytime and anywhere. STB CLOUD outperforms common Software as a Service (SaaS) options in the market. By integrating DeepMatcher ®, an AI-driven small molecule drug discovery platform, this new service has automated AI computing function within its own supercomputing hardware environment and database into the cloud system. Improving standardization, simplification and automation of the existing computer-aided drug discovery (CADD) process optimizes the drug discovery and development process far better in terms of time, cost, accuracy and resources. It generates a comprehensive automatic report, including active substance candidates with users’ minimum input, for instance, only by inputting the name of the target protein related to a disease of interest. “We live in a rapidly changing world with constant disruptions by new and advanced technologies. STB CLOUD is an instant game changer for faster, easier and more accurate drug discovery. Investing in technologies like this further supports clinical trials critical for making lifesaving drugs in a timely manner,” said the CEO of Syntekabio, Jongsun Jung, Ph.D. “This landmark achievement will undoubtedly strengthen Syntekabio’s position in the competitive AI drug discovery industry. Bringing STB CLOUD to the global marketplace has been a tremendous endeavor by our exceptional scientists and engineers.” For the evaluation of automated drug discovery performance in STB CLOUD, DeepMatcher ® was used for 10 target proteins with a library of 120 million compounds available for quick purchase. The evaluation included compounds with known binding affinity as positive controls in the compound library and tracked the number of positive controls recovered during the DeepMatcher ® process, which is comprised of three steps: 3D screening, optimal pose and validation. After the first step, the average recovery rate was 31 percent among 1,000 top-ranked candidates. At the completion of the final validation step (MD simulation), the recovery rate resulted in an average of 16 percent among 200 final-ranked candidates for 10 targets. These outstanding results prove not only the power of STB CLOUD but the potential of DeepMatcher ® itself in the overall drug discovery industry. Syntekabio is already working on further strengthening STB CLOUD, with a neoantigen prediction platform (NEO-ARS™) and a multivariate biomarker prediction and discovery platform (PGM-ARS™), to be used for supporting clinical trials with a selection of patients in the near future. Additionally, the company’s new high-performance supercomputing center with 10,000 CPU/GPU computing servers is underway to be completed in the first half of 2023. For business development meetings and information about Syntekabio’s products and services, contact the New York office at +1 (212) 371-2544 or admin@syntekabiousa.com. More information about STB CLOUD is available at cloud.syntekabio.com. SyntekaBio is a global artificial intelligence (AI) and big data-based drug discovery and development company, headquartered in South Korea since 2009, with its U.S. operations bringing innovative technologies and science to create transformative medicines worldwide that are compliant with international standards to cure diseases and improve people's lives. Find out more about DeepMatcher®, NEO-ARS™, NGS-ARS™ and PGM-ARS™ at www.syntekabio.com. Contact Details Syntekabio USA | WMSG Sabina Lee +1 201-408-5342 wgroup@wmedical.org Company Website https://www.syntekabio.com/eng

December 16, 2022 11:00 AM Eastern Standard Time

Portugal National Funder FCT Agrees Transformative Agreement with Elsevier

Elsevier

Elsevier, a global leader in research publishing and information analytics has entered into a transformative agreement with b-on to enable continued reading access for researchers affiliated with b-on institutions and open access publishing. This is the first time Elsevier has signed a transformative agreement to support Portugal. It will benefit the member institutions with access to Elsevier's extensive collection of journals on ScienceDirect. The cost of publishing open access is covered under the terms of this agreement up to a pre-set annual cap. When publishing open access in hybrid journals, eligible corresponding authors do not have to pay an article publishing charge (APC). The new three-year contract will run until 31 st October 2024. Joana Novais, Manager of the b-on Consortium said: “This agreement lays an important stepping stone in the direction of Open Access in Portugal. It is a great honour for b-on to be able to contribute to this transition to OA by providing the authors of its member institutions the possibility to publish an annual average of 2000 OA articles in hybrid journals without incremental costs.” The b-on Consortium was founded in 2004 and represents 64 institutions, mainly higher education and research institutions across Portugal. It is managed by FCCN, a unit of FCT – Foundation for Science and Technology. William Rubens, Vice President, Elsevier said: "We are delighted to be working with the b-on Consortium to support their open access ambitions. We are thrilled to have agreed to our first Open Access agreement with them to ensure access to high-quality research and enable Portuguese researchers to publish with Elsevier, enabling them to share their findings globally." Elsevier aims to find the right solutions to meet the diverse needs of academic institutions, students, researchers, and funders worldwide while ensuring published research remains trusted and of high quality. Our approach with all customers is to understand their objectives and work with them to achieve these in an economically sustainable way while preserving the quality, integrity, and sustainability of the peer-review publishing system. For more on how Elsevier supports open access, please visit our website. About b-on B-on provides unlimited and permanent access to the full texts of thousands of scientific journals and online ebooks from some of the most important content providers, through subscriptions negotiated at national level. It started operating in March 2004 and is today a reference in access to international scientific information. It brings together higher education institutions, R&D institutions, hospitals, public institutions and private non-profit institutions. B-on currently reaches around 380.000 individuals affiliated with its 64 member institutions. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions, and funders. Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, LCUA, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,700+ digitized journals, including The Lancet and Cell; our 40,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com Contact Details Elsevier Communications, UK Andrew Davis +44 7393 242466 andrew.davis@elsevier.com Company Website https://www.elsevier.com/

December 16, 2022 08:20 AM Eastern Standard Time

Ellie Diagnostics Appoints Pat McCarthy as Chief Commercial Officer

Ellie Diagnostics

Ellie Diagnostics, the leading independent diagnostics services provider for veterinarians, today announced that Pat McCarthy has been named Chief Commercial Officer. In this new role, Mr. McCarthy will drive commercial operations and strategic initiatives across the entire organization. He has more than 25 years of experience leading commercial teams and corporate accounts business strategy with high-profile companies such as PSIvet, Pet Partners LLC and IDEXX Laboratories. “On behalf of our medical board, investors, and the entire Ellie team, we are pleased to welcome Pat to our group,” said Founder and Chief Executive Officer Mark DeCourcy. “He brings a wealth of animal health, and commercial experience to Ellie Diagnostics that will be extremely valuable as the company continues to grow, and strengthen its commercial strategy.” “I am very excited to join the Ellie Diagnostics team as CCO,” said Chief Commercial Officer Pat McCarthy. “The growth potential is astonishing, and the value of service Ellie provides veterinarians is tremendous, given its advanced laboratory technology and passionate people. I look forward to strengthening our commercial strategy, and execution for the tremendous growth that is forecasted for 2023 and beyond.” About Ellie Diagnostics Ellie Diagnostics is the fastest growing independent veterinary diagnostics company in the United States, providing innovative services to veterinarians nationwide. Ellie provides next-day lab results, complimentary shipping, pathology consultations, data protection, mobile access to orders and results and innovative laboratory reporting. Their comprehensive test menu includes routine lab testing, histopathology, cytology, microbiology, and a wide variety of specialty tests. To learn more, visit www.elliediagnostics.com. Contact Details Ellie Diagnostics Jeff Gwynn, Vice President of Marketing +1 972-619-9969 jgwynn@elliediagnostics.com

December 15, 2022 12:00 PM Eastern Standard Time